Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)

Keros Therapeutics' Capital Expenditures history spans 7 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 588.58% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached $5000.0, down 99.74%, while the annual FY2025 figure was $5000.0, 99.74% down from the prior year.
  • Capital Expenditures reached -$1.4 million in Q4 2025 per KROS's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q3 2024 to a low of -$1.4 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $252631.6, with a median of $159000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: skyrocketed 2471.43% in 2021, then tumbled 11836.36% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $159000.0 in 2021, then soared by 672.33% to $1.2 million in 2022, then crashed by 56.11% to $539000.0 in 2023, then tumbled by 46.38% to $289000.0 in 2024, then crashed by 588.58% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Capital Expenditures are -$1.4 million (Q4 2025), $1.4 million (Q3 2025), and -$551000.0 (Q2 2025).